Helen L Zhang1, Leigh Cressman2, Ebbing Lautenbach3. 1. Division of Infectious Diseases, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Electronic address: helen.zhang1@pennmedicine.upenn.edu. 2. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 3. Division of Infectious Diseases, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract
OBJECTIVES: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections. METHODS: This study included adult patients with MVB-susceptible CRE infection who received ≥48 h of MVB. Clinical and microbiological outcomes were ascertained via chart review. RESULTS: Among 15 patients with CRE infection who were treated with MVB, 9 (60.0%) had a positive clinical response. Among five patients with CRE bone and joint infection, three (60.0%) experienced a positive clinical response. One patient developed a microbiologically confirmed recurrent CRE infection and one patient developed Clostridioides difficile infection. CONCLUSION: MVB was well tolerated and effective for the majority of patients in this case series.
OBJECTIVES: Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections. METHODS: This study included adult patients with MVB-susceptible CRE infection who received ≥48 h of MVB. Clinical and microbiological outcomes were ascertained via chart review. RESULTS: Among 15 patients with CRE infection who were treated with MVB, 9 (60.0%) had a positive clinical response. Among five patients with CRE bone and joint infection, three (60.0%) experienced a positive clinical response. One patient developed a microbiologically confirmed recurrent CRE infection and one patient developed Clostridioides difficile infection. CONCLUSION: MVB was well tolerated and effective for the majority of patients in this case series.
Authors: Deanna J Buehrle; Ryan K Shields; Lloyd G Clarke; Brian A Potoski; Cornelius J Clancy; M Hong Nguyen Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Ryan K Shields; Erin K McCreary; Rachel V Marini; Ellen G Kline; Chelsea E Jones; Binghua Hao; Liang Chen; Barry N Kreiswirth; Yohei Doi; Cornelius J Clancy; M Hong Nguyen Journal: Clin Infect Dis Date: 2020-07-27 Impact factor: 9.079
Authors: Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Keith S Kaye; Tanaya Bhowmick; Symeon Metallidis; Susan C Bleasdale; Olexiy S Sagan; Viktor Stus; Jose Vazquez; Valerii Zaitsev; Mohamed Bidair; Erik Chorvat; Petru Octavian Dragoescu; Elena Fedosiuk; Juan P Horcajada; Claudia Murta; Yaroslav Sarychev; Ventsislav Stoev; Elizabeth Morgan; Karen Fusaro; David Griffith; Olga Lomovskaya; Elizabeth L Alexander; Jeffery Loutit; Michael N Dudley; Evangelos J Giamarellos-Bourboulis Journal: JAMA Date: 2018-02-27 Impact factor: 56.272
Authors: Olga Lomovskaya; Dongxu Sun; Debora Rubio-Aparicio; Kirk Nelson; Ruslan Tsivkovski; David C Griffith; Michael N Dudley Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Sara Alosaimy; Sarah C J Jorgensen; Abdalhamid M Lagnf; Sarah Melvin; Ryan P Mynatt; Travis J Carlson; Kevin W Garey; David Allen; Veena Venugopalan; Michael Veve; Vasilios Athans; Stephen Saw; Christine N Yost; Susan L Davis; Michael J Rybak Journal: Open Forum Infect Dis Date: 2020-02-19 Impact factor: 3.835
Authors: Richard G Wunderink; Evangelos J Giamarellos-Bourboulis; Galia Rahav; Amy J Mathers; Matteo Bassetti; Jose Vazquez; Oliver A Cornely; Joseph Solomkin; Tanaya Bhowmick; Jihad Bishara; George L Daikos; Tim Felton; Maria Jose Lopez Furst; Eun Jeong Kwak; Francesco Menichetti; Ilana Oren; Elizabeth L Alexander; David Griffith; Olga Lomovskaya; Jeffery Loutit; Shu Zhang; Michael N Dudley; Keith S Kaye Journal: Infect Dis Ther Date: 2018-10-01